Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification
Key Highlights
- ➤Genenta (GNTA) received Nasdaq deficiency notice after ADSs stayed below $1 for 30 business days
- ➤Nasdaq granted Genenta until April 14, 2027, to restore the $1 minimum bid price
- ➤Genenta shareholders approved a potential 1-for-10 to 1-for-20 reverse stock split
- ➤Genenta warns it may not regain compliance or remain listed on Nasdaq
MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
The notification was issued because the closing bid price of the Company’s American Depositary Shares (“ADSs”) was below $1.00 per ADS for 30 consecutive business days, from September 3, 2026 through October 15, 2026. The notification does not result in the immediate delisting of the Company’s ADSs, which will continue to trade on the Nasdaq Capital Market under the symbol “GNTA,” subject to the Company’s continued compliance with other applicable listing requirements.
Get started
Create a free account to read the full story.